Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16715999 | 0.89 | TSHR (0.39) | TSHRKDM4EALOX15ACMSDTDP1 | |
| SCHEMBL13080910 | 0.85 | CYP1A2 (0.40) | TSHRKDM4EALOX15ACMSDTDP1 | |
| SCHEMBL4036991 | 0.80 | PTPRA (0.56) | KDM4ETDP1SMN1; SMN2PTPRALMNA | |
| SCHEMBL6276435 | 0.74 | TSHR (0.67) | TSHRKDM4EALOX15TDP1KMO | |
| SCHEMBL4967701 | 0.74 | TSHR (0.67) | TSHRKDM4EALOX15TDP1KMO | |
| SCHEMBL8076205 | 0.74 | TSHR (0.67) | TSHRKDM4EALOX15TDP1KMO | |
| SCHEMBL27584150 | 0.72 | PTPN1 (0.57) | TSHRKDM4EALOX15TDP1SMN1; SMN2 | |
| SCHEMBL13649466 | 0.70 | KMO (0.46) | KMO | |
| SCHEMBL13052097 | 0.69 | KDM4E (0.54) | TSHRKDM4EALOX15ACMSDTDP1 | |
| Naphthalene SCHEMBL2936422 | 0.69 | SMN1; SMN2 (0.65) | TSHRKMOSMN1; SMN2PTPRACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034873-B2 | Pyridazine and pyrrole compounds, processes for obtaining them and uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2015-05-19 | — | — | US | disclosed |
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298562-A1 | Pyridazine and Pyrrole Compounds, Processes For Obtaining Them and Uses | PPOX, PNPO, PLPBP | TSHR 3126/4885KDM4E 2333/4885ALOX15 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.